In this issue:
Early identification of malignant transformation in smoldering myeloma
Smoldering myeloma current treatment algorithms
Post-ASCT herpes zoster prophylaxis is safe and effective
The IMWG frailty score has utility in relapsed/refractory disease
Indirect comparison finds favourable PFS with D-Pd vs D-Vd/Vd for RRMM
Belantamab mafodotin-induced ocular toxicity is common
Chromosome 1q21 amplification confers an adverse prognosis
Link between myelofibrosis and extramedullary disease in myeloma
Outcomes for IgD myeloma treated with novel therapeutic regimens
Daratumumab combination confers PFS benefit regardless of cytogenetic risk
Please login below to download this issue (PDF)